
Antonello Domenico Cabras

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/655079/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. Clinical Cancer Research, 2009, 15, 4415-4422.	7.0	189
2	Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion. Annals of Surgical Oncology, 2006, 13, 229-237.	1.5	144
3	Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death. Cancer Research, 2010, 70, 9062-9072.	0.9	126
4	Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). European Journal of Cancer, 2013, 49, 3140-3148.	2.8	110
5	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood, 2009, 113, 18-27.	1.4	99
6	Pseudomyxoma Peritonei. Annals of Surgery, 2009, 249, 243-249.	4.2	90
7	Cytoreductive Surgery with Selective Versus Complete Parietal Peritonectomy Followed by Hyperthermic Intraperitoneal Chemotherapy in Patients with Diffuse Malignant Peritoneal Mesothelioma: A Controlled Study. Annals of Surgical Oncology, 2012, 19, 1416-1424.	1.5	85
8	Diffuse malignant mesothelioma of the peritoneum. Cancer, 2005, 104, 2181-2188.	4.1	82
9	Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3. Journal of Investigative Dermatology, 2014, 134, 1893-1902.	0.7	74
10	Lymph Node Metastases in Diffuse Malignant Peritoneal Mesothelioma. Annals of Surgical Oncology, 2010, 17, 45-53.	1.5	72
11	Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia, 2007, 21, 1802-1811.	7.2	66
12	B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. Human Pathology, 2010, 41, 621-631.	2.0	60
13	The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Annals of Surgical Oncology, 2016, 23, 1468-1473.	1.5	59
14	Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Annals of Surgical Oncology, 2009, 16, 463-472.	1.5	46
15	The Germinal centreâ€derived lymphomas seen through their cellular microenvironment. British Journal of Haematology, 2009, 145, 468-480.	2.5	44
16	HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. Blood, 2015, 125, 1768-1771.	1.4	40
17	Species identification of mycobacteria in paraffin-embedded tissues: frequent detection of nontuberculous mycobacteria. Modern Pathology, 2005, 18, 274-282.	5.5	38
18	High response rate and manageable toxicity with an intensive, shortâ€ŧerm chemotherapy programme for Burkitt's lymphoma in adults. British Journal of Haematology, 2004, 126, 815-820.	2.5	35

#	Article	IF	CITATIONS
19	PCR analysis of IgH-gene rearrangements in small lymphoid infiltrates microdissected from sections of paraffin-embedded bone marrow biopsy specimens. Human Pathology, 2000, 31, 847-853.	2.0	30
20	Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. European Journal of Cancer, 2010, 46, 2837-2848.	2.8	30
21	Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood, 2011, 118, 4421-4430.	1.4	30
22	Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression. Cancer Research, 2014, 74, 130-140.	0.9	27
23	Herpesvirus 8-Associated Penile Kaposi's Sarcoma in an HIV-Negative Patient. American Journal of Dermatopathology, 2003, 25, 28-31.	0.6	26
24	Poorly differentiated synovial sarcoma of the vagina: first reported case with immunohistochemical, molecular and ultrastructural data. Histopathology, 2007, 50, 808-810.	2.9	23
25	Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World Journal of Gastrointestinal Oncology, 2010, 2, 76.	2.0	22
26	Epstein-Barr Virus–Negative Hodgkin's Lymphoma After Mycosis Fungoides: Molecular Evidence for Distinct Clonal Origin. Modern Pathology, 2001, 14, 91-97.	5.5	21
27	Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray. Annals of Surgical Oncology, 2015, 22, 4344-4351.	1.5	21
28	Rapid Identification of Wilson's Disease Carriers by Denaturing High-Performance Liquid Chromatography. Preventive Medicine, 2002, 35, 278-284.	3.4	18
29	Oligoclonality of a "composite" gastric diffuse large B-cell lymphoma with areas of marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 440, 209-214.	2.8	17
30	Differentiating germinal centerâ€derived lymphomas through their cellular microenvironment. American Journal of Hematology, 2009, 84, 435-438.	4.1	16
31	Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy. International Journal of Colorectal Disease, 2009, 24, 69-77.	2.2	16
32	Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with γc cytokines. Blood, 2006, 107, 602-609.	1.4	15
33	Quality assessment in diagnostic molecular pathology: experience from a German-Austrian-Swiss multicenter trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 46-51.	2.8	14
34	Alternate Clonal Dominance in Richter Transformation Presenting as Extranodal Diffuse Large B-Cell Lymphoma and Synchronous Classic Hodgkin Lymphoma. American Journal of Clinical Pathology, 2014, 142, 227-232.	0.7	6
35	Radioimmunotherapy and secondary leukemia: A case report. Leukemia Research, 2010, 34, e1-e4.	0.8	4
36	High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression. Blood Cancer Journal, 2016, 6, e491-e491.	6.2	4

#	Article	IF	CITATIONS
37	Advances in Clinical Research and Management of Diffuse Peritoneal Mesothelioma. , 2007, 169, 137-155.		3
38	In Reply: Five Reasons Why Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Must Be Regarded as the New Standard of Care for Diffuse Malignant Peritoneal Mesothelioma. Annals of Surgical Oncology, 2010, 17, 1713-1714.	1.5	2
39	MALT lymphoma and Kaposi Sarcoma in an HIV-negative patient. American Journal of Hematology, 2010, 85, 815-817.	4.1	2
40	Dove in Flight: Who Will Save the Dove?. International Journal of Surgical Pathology, 2006, 14, 144-144.	0.8	0